Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation.
Galectin-3 is a biomarker of fibrosis and atrial remodeling, involved in the mechanisms of initiation and maintenance of atrial fibrillation (AF). We sought to study the accuracy of galectin-3 level in predicting recurrences of AF after ablation. Serum concentrations of galectin-3 were determined in a consecutive series of patients addressed for AF ablation in our center. After a 3-month blanking period, recurrences of atrial arrhythmias were collected during the first year in all patients, using Holter monitoring at 3, 6 months and 12 months. A total of 160 patients were included, with a mean galectin-3 rate was 14.4 ± 5.6 ng/mL. At 12-month, 55 patients (34%) had reexperienced sustained atrial arrhythmia. Only higher galectin-3 level (HR = 1.07 [1.01-1.12], p = 0.02) and larger left atrial diameter (HR = 1.07 [1.03-1.12], p = 0.001) independently predicted recurrence. Patients with both galectin-3 level <15 ng/mL and left atrial diameter <40 millimeters had a 1-year arrhythmia-free survival rate - after a single procedure without anti-arrhythmic drug - of 91%, as compared with 41% in patients with galectin-3 ≥ 15 and left trial diameter ≥40 (p < 0.0001), whether AF was paroxysmal or persistent. Galectin-3 and left atrial diameters, rather than clinical presentation of AF, predict recurrences after ablation.
Cardiology Department, Trousseau Hospital, François Rabelais University, Tours, France.
Nicolas
N
Clementy
Cardiology Department, Trousseau Hospital, François Rabelais University, Tours, France.
Nazih
N
Benhenda
Biochemistry Department, Trousseau Hospital, François Rabelais University, Tours, France.
Eric
E
Piver
Cardiology Department, Trousseau Hospital, François Rabelais University, Tours, France.
Bertrand
B
Pierre
Cardiology Department, Trousseau Hospital, François Rabelais University, Tours, France.
Anne
A
Bernard
Cardiology Department, Trousseau Hospital, François Rabelais University, Tours, France.
Laurent
L
Fauchier
Biochemistry Department, Trousseau Hospital, François Rabelais University, Tours, France.
Jean-Christophe
JC
Pages
Cardiology Department, Trousseau Hospital, François Rabelais University, Tours, France.
Dominique
D
Babuty
J Am Coll Cardiol. 2012 Apr 3;59(14):1295-301
22464257
Clin Chim Acta. 2014 Feb 15;429:189-93
24365381
Curr Opin Cardiol. 2014 Jan;29(1):20-7
24281345
Europace. 2015 Oct;17(10):1541-7
25921557
Clin Res Cardiol. 2015 Oct;104(10):871-6
25876528
Am Heart J. 2014 May;167(5):729-34.e1
24766984
J Am Coll Cardiol. 2011 Mar 15;57(11):e101-98
21392637
Clin Biochem. 2015 Aug;48(12):818-22
25952321
J Cardiovasc Electrophysiol. 2015 Jun;26(6):635-40
25684038
Europace. 2012 May;14(5):638-45
22117033
Am J Cardiol. 2015 Jul 1;116(1):163
25956621
N Engl J Med. 2015 May 7;372(19):1812-22
25946280
J Am Coll Cardiol. 2011 Oct 18;58(17):1741-9
21996384
J Pharmacol Exp Ther. 2014 Nov;351(2):336-43
25194021
PLoS One. 2015 Apr 15;10(4):e0123574
25875595
JAMA. 2014 Feb 5;311(5):498-506
24496537
Int J Cardiol. 2015 Jan 20;179:351-7
25464485
J Am Coll Cardiol. 2014 Jun 10;63(22):2335-45
24613319